Member Info for B_A_B_A

Fair enough, and your sentiments again are warm and welcomed by all I’m sure. Just seemed a little duplicitous earlier when you’d posted on the other board that NCYT investors could gain a lot by selling here and investing there, and then coming over here and using words such as losses, and saying that averaging down might not be a good idea, good money after bad etc. Kind of undermines the subsequent well wishing posts when you talk elsewhere about CD players and MP3s, no coming back for most investors here (NCYT) and so on, if you see where I’m coming from. To reiterate, I’m invested in both.

Warm sentiments covidopportunist, but I wouldn’t say that anybody has lost anything here, unless they were to sell out now/ before a recovery.

I suppose though that at this price, and with cash at hand and known Q1 revenues, all imaginable bad news is fully priced in and then some. Can’t say the same for other stocks such as AVCT, and whilst I hold there I can’t help having a feeling that AVCT at its current SP feels a lot like NCYT did at £12 - namely that everything that might possibly go right is fully priced in. Might sell some there and add more here next week in fact.

Considering some of the negative connotations of other information in the RNS, namely around the DHSC contract and lower revenue forecasts for 2021, I’d have thought that if the company is working on something as headline grabbing and topical as an antigen LFT for COVID-19 then it would have been more than inferred in the RNS, it would have been shouted about to provide positive balance against the negative news. On that basis I’d say no, it’s just a reference to what we know and have already been told is being worked on.

Selling out when things appear to be turning downwards and buying back in when the perceived bottom is in is the traders MO though, and I strongly believe that all those prolific Twitter stock posters are traders. We, as investors, have a different philosophy. Each to their own I suppose.

Our antibody LFT isn’t going to be much use for pubs, sporting venues etc.; it won’t give any indication of whether the individual is carrying an infection at all.

The spread is a bit higher than normal but still isn’t that big at present, ~1.2p.

To put that into context, a £1 sp would value the company at ~1/4 of the valuation of BP. So, what do you think the answer might be?

Does OTC qualify as a dual listing? I thought not as it’s just a market where trades are facilitated directly between brokers.

Here is a description:
‘Over-the-counter (OTC) refers to the process of how securities are traded for companies not listed on a formal exchange. Securities that are traded over-the-counter are traded via a dealer network as opposed to on a centralized exchange’

To me this means that it is a direct transaction between share owners; Nasdaq would be different and shares would be allocated to the US exchange rather than being borrowed from London as far as I understand - not saying additional shares are created just that some are permanently transferred.

The ODX contract is for a different type of LFT to the one that Nova will be releasing. Ours will not be for the purpose of telling you whether you have the virus or not (so not the type that the govt has been championing regularly as one of the things that will help us get back to normal).

Okay, got ask then - you are choo choo the cartoon cat aren’t you? Can’t see any other rationale for you to keep mentioning him/her. You’ve gained a follower though I see. Winner!

An individual with 16 followers, who has also recently tweeted about battenburg cake. Who cares?

By means of a merger with a Nasdaq listed cash shell

Where to buy as in from which broker surely? I’d imagine that those are the questions being asked, they won’t be receiving questions asking from which market to buy arbkf!!

USA is at 4.00 live price, so almost identical. CNBC shows live price.

It didn’t change that quickly (ie within 30 seconds). Thanks though.

I’m seeing $3.29 live price on CNBC

PROmate was the ‘fix’ to make the previous deal work for most of the NHS end users. Rollout was slowed down because of workflow issues, PROmate is fixing it and enabling phase 1 to resume again as far as I understand it?

In the example that Tommy described, which I’ve seen a few times with ARB during rises also, HL are doing it for you effectively. They are getting you a best sell price from one MM which is higher than the lowest buy from another. If you are playing with a significant amount it would be worthwhile, to account for the fees. I see gaps of up to 0.25p sometimes.

Yes, during the period a few weeks ago when the price was climbing rapidly and daily I was often getting quotes to sell that were marginally higher than buy quotes. Didn’t do either to prove that it would complete but I believe that it would have.

The actual spread from dummy buy and sell is less than 0.5p; this is almost always the case on ARB.